Morningstar brands and products Company Portfolio ...

SOOPR is a rapid-onset, long-acting rescue agent specifically designed to address overdose from synthetic opioids, including oral fentanyl. SOOPR utilizes a proprietary long-acting naloxone ...

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval ...

longer-acting opioid rescue therapy specifically intended to treat fentanyl overdose." Data from in vivo proof-of-concept studies of SOOPR demonstrated a more rapid onset of action versus naloxone ...

The Trump administration’s plan to address the opioid crisis focuses on preventing overdose deaths, but neglects the ...

FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve clinical outcomes and QOL.

The availability of suzetrigine may represent a critical step in addressing the nation’s pain management crisis. While questions remain about its cost, adoption, and long-term efficacy, its novel ...

Action-thriller “King Ivory ... Set against the backdrop of the opioid epidemic as fentanyl floods the market, “King Ivory” follows Tulsa drug cop Layne West (Dale) whose son Jack (Jones ...

The cuts came as our nation is finally turning the corner on the opioid crisis, which peaked during COVID but has returned to 2020 levels. The federal Centers for Disease Control and Prevention ...

New study shows that dysfunction of protective immune cells in GI tract may contribute to onset of inflammation in Crohn's disease. A research team led by Mount Sinai has uncovered mechanisms of ...

Dating back to January 2021, the state of Florida negotiated and received more than $3 billion from companies accused of contributing to the nationwide opioid crisis. In 2024, the Nassau County ...